RxDoctor Payments DataLook up a doctor →

Carlos Santos, MD

Pulmonary Disease · North Miami Beach, FLNPI 1851343578

Payments from drug & device makers

$619,512in general payments, 2019–2025

Across 1,809 payments — averaging $342.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$307K
  • GSK$120K
  • Mallinckrodt Hospital Products Inc.$106K
  • Mallinckrodt Enterprises LLC$25K
  • Actelion Pharmaceuticals US, Inc.$12K
  • Mylan Specialty L.p.$8K
  • plus $40K from 47 others

What the payments were for

  • Consulting fees$2,9301%
  • Speaking & faculty fees$252,44381%
  • Travel & lodging$6,9602%
  • Food & beverage$48,75516%
  • Education$1,0430%
  • Gifts$530%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$619,512 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$198,195
Medicare patients
294
Services billed
2,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ActharCorticotropin14$1,000,618
Trelegy ElliptaFluticasone/Umeclidin/Vilanter1,135$828,275
Breztri AerosphereBudesonide/Glycopyr/Formoterol517$352,297
UptraviSelexipag13$302,608
NucalaMepolizumab71$263,593
OpsumitMacitentan18$225,515
Dupixent PenDupilumab55$220,422
TezspireTezepelumab-Ekko43$181,815
ArikayceAmikacin Liposomal/Neb.Accessr12$179,685
XolairOmalizumab38$155,813
Breo ElliptaFluticasone/Vilanterol335$154,095
OfevNintedanib Esylate12$146,878
SymbicortBudesonide/Formoterol Fumarate401$106,238
EliquisApixaban153$76,368
Ambrisentan32$71,716

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$120,323$1,312,6351,710 claims
Mallinckrodt Hospital Products Inc.Acthar$106,361$1,000,61814 claims
AstraZenecaBreztri Aerosphere, Tezspire, Symbicort$6,332$640,350961 claims
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$12,109$528,12331 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat$1,912$257,051211 claims
Insmed, Inc.Arikayce$1,985$179,68512 claims
PfizerEliquis$87$76,368153 claims
AbbVieCreon, Linzess$851$59,27242 claims
Lilly USA, LLCMounjaro, Trulicity$21$29,07528 claims
NovartisEntresto$193$15,76722 claims
MerckBelsomra$364$9,04020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in North Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →